TerminatedPhase 3

Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Stopped: Due to recruiting problems and the introduction of new treatment strategies (ranibizumab and dexamethasone implant).

Norway34 participantsStarted 2006-11

Plain-language summary

The purpose of this study is to determine whether pars plana vitrectomy in combination with triamcinolone acetate is effective in the treatment of macular edema due to branch retinal vein occlusion.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Macular edema secondary to BRVO * Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart * Duration no shorter than 3 months * Duration no longer than 12 months Exclusion Criteria: * Proliferations in study eye * Blod in vitreous cavity * Previous fundus laser treatment * BRVO with over 180˚ of ischemia on FA * Age under 18 * Other eye condition which contribute to relevant loss of visual acuity

What they're measuring

Visual acuity (ETDRS)

Timeframe: 12 and 36 Months

Trial details

NCT IDNCT00642226

SponsorHelse Stavanger HF

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2013-11

View on ClinicalTrials.gov More Branch Retinal Vein Occlusion trials